Search results for "benzoxazine"

showing 10 items of 78 documents

Synthesis of the New Ring System 2-Oxo-[1,4]oxazino[3,2-e]indole, Heteroanalogue of Angelicin

2009

A convenient synthesis of the 2-oxo-[1,4]oxazino[3,2-e]indole ring system, an heteroanalogue of Angelicin, is reported. Our synthetic approach consisted of the annelation of the oxazine ring on the indole moiety using 4-amino-5-hydroxy indoles as building blocks. The antiproliferative activity of the new compounds either in the dark or under UVA irradiation was investigated.

Indole testAnnulationStereochemistryOrganic Chemistry1; 4-Oxazinoindoles; 1; 4-Benzoxazines; Angelicin heteroanalogue; 4-Amino-5-hydroxy indoles114-Benzoxazine14-OxazinoindoleRing (chemistry)Biochemistry4-Oxazinoindoles4-Benzoxazineschemistry.chemical_compoundAngelicinchemistryDrug DiscoveryMoiety4-Amino-5-hydroxy indolesUva irradiationAngelicin heteroanalogue
researchProduct

The Peptide Hemopressin Acts through CB1Cannabinoid Receptors to Reduce Food Intake in Rats and Mice

2010

Hemopressin is a short, nine amino acid peptide (H-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) isolated from rat brain that behaves as an inverse agonist at the cannabinoid receptor CB1, and is shown here to inhibit agonist-induced receptor internalization in a heterologous cell model. Since this peptide occurs naturally in the rodent brain, we determined its effect on appetite, an established central target of cannabinoid signaling. Hemopressin dose-dependently decreases night-time food intake in normal male rats and mice, as well as in obeseob/obmale mice, when administered centrally or systemically, without causing any obvious adverse side effects. The normal, behavioral satiety sequence is …

LeptinMaleTime FactorsCannabinoid receptormedicine.medical_treatmentPharmacologyRats Sprague-DawleyEatingHemoglobinsMicechemistry.chemical_compoundPiperidinesReceptor Cannabinoid CB1RimonabantChlorocebus aethiopsDronabinolReceptorMice KnockoutBehavior AnimalDrug Administration RoutesGeneral NeuroscienceArticlesEndocannabinoid systemCircadian RhythmProtein TransportCOS CellsRimonabantmedicine.drugAgonistmedicine.medical_specialtymedicine.drug_classMorpholinesGreen Fluorescent ProteinsDrinking BehaviorHyperphagiaNaphthalenesBiologyTransfectionInternal medicinemedicineAnimalsInverse agonistAnalysis of VariancePsychotropic DrugsDose-Response Relationship DrugCyclohexanolsPeptide FragmentsHemopressinBenzoxazinesRatsMice Inbred C57BLEndocrinologychemistryPyrazolesCannabinoidFood DeprivationThe Journal of Neuroscience
researchProduct

Involvement of TRPV1 channels in the activity of the cannabinoid WIN 55,212-2 in an acute rat model of temporal lobe epilepsy

2016

The exogenous cannabinoid agonist WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN), has revealed to play a role on modulating the hyperexcitability phenomena in the hippocampus. Cannabinoid-mediated mechanisms of neuroprotection have recently been found to imply the modulation of transient receptor potential vanilloid 1 (TRPV1), a cationic channel subfamily that regulate synaptic excitation. In our study, we assessed the influence of pharmacological manipulation of TRPV1 function, alone and on WIN antiepileptic activity, in the Maximal Dentate Activation (MDA) acute model of temporal lobe epilepsy. Our r…

Male0301 basic medicineAgonistCannabinoid Receptor Modulatorsmedicine.drug_classMorpholinesmedicine.medical_treatmentTRPV1TRPV Cation ChannelsHippocampusNaphthalenesPharmacologySettore BIO/09 - FisiologiaNeuroprotection03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReceptor Cannabinoid CB1Hippocampus Temporal lobe epilepsy Cannabinoids TRPV1 Capsaicin ElectrophysiologyMembrane Transport ModulatorsCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarWIN 55212-2ChemistryElectric StimulationBenzoxazinesDisease Models Animal030104 developmental biologyEpilepsy Temporal LobeNeurologyAcute DiseaseAnticonvulsantslipids (amino acids peptides and proteins)Neurology (clinical)CannabinoidCapsaicinCapsazepineNeurosciencepsychological phenomena and processes030217 neurology & neurosurgerymedicine.drugEpilepsy Research
researchProduct

Reward-related limbic memory and stimulation of the cannabinoid system: An upgrade in value attribution?

2018

While a lot is known about the mechanisms promoting aversive learning, the impact of rewarding factors on memory has received comparatively less attention. This research investigates reward-related explicit memory in male rats, by taking advantage of the emotional-object recognition test. This is based on the prior association, during conditioned learning, between a rewarding experience (the encounter with a receptive female rat) and an object; afterwards rat discrimination and recognition of the â emotional objectâ is recorded in the presence of a novel object, as a measure of positive limbic memory formation. Since endocannabinoids are critical for processing reward and motivation, the co…

Male0301 basic medicineMorpholinesmedia_common.quotation_subjectmedicine.medical_treatmentConditioning ClassicalEmotionsStimulationNaphthalenes03 medical and health sciences0302 clinical medicineRewardMemoryAvoidance LearningLimbic SystemmedicineExplicit memoryAnimalsPharmacology (medical)Rats WistarAssociation (psychology)media_commonCannabinoid Receptor AgonistsPharmacologyMotivationAddictionreward-conditioningNoveltyRecognition PsychologyObject (computer science)emotional-object recognitionBenzoxazinesRatsPsychiatry and Mental health030104 developmental biologySettore BIO/14 - FarmacologiaFemaleCannabinoidPsychologyAttributionNeurosciencecannabinoid stimulationpsychological phenomena and processes030217 neurology & neurosurgeryEndocannabinoidsJournal of Psychopharmacology
researchProduct

Neuronal nitric oxide synthase is involved in CB/TRPV1 signalling: Focus on control of hippocampal hyperexcitability

2017

Cannabinoids (CB), transient receptors potential vanilloid type 1 (TRPV1) and nitric oxide (NO) were found to be interlinked in regulating some neuronal functions such as membrane excitability and synaptic transmission. TRPV1 play a fundamental role since it represents a synaptic target for CB that triggers several downstream cellular pathways. In this regard, recent evidence report that TRPV1 could influence NO production by modulating neuronal NO synthase (nNOS) activity. In the present research, we pointed to manipulate nNOS function to assess its role on TRPV1 signalling in hyperexcitability conditions elicited in the dentate gyrus of hippocampal formation. The activation of TRPV1 recep…

Male0301 basic medicineTime FactorsAction PotentialsHippocampusStimulationNitric Oxide Synthase Type IHippocampal formationHippocampusSettore BIO/09 - Fisiologia0302 clinical medicineRosaniline DyesEnzyme InhibitorsChemistryElectrophysiologyNeurologyExcitatory postsynaptic potentialAnticonvulsantsSignal TransductionAgonistIndazolesmedicine.drug_classMorpholinesTRPV1TRPV Cation ChannelsMaximal Dentate ActivationNaphthalenesNeurotransmissionArginineTransient receptors potential vanilloid type 103 medical and health sciencesHippocampumedicineAnimalsRats WistarCannabinoidAnalysis of VarianceCannabinoidsDentate gyrusNitric oxideElectric StimulationBenzoxazinesRats030104 developmental biologynervous systemSensory System AgentsCannabinoids; Electrophysiology; Hippocampus; Maximal Dentate Activation; Nitric oxide; Transient receptors potential vanilloid type 1; Neurology; Neurology (clinical)Neurology (clinical)CapsaicinNeuroscience030217 neurology & neurosurgeryEpilepsy Research
researchProduct

Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice

2010

AbstractBackgroundNumerous reports indicate that MDMA users consume other psychoactive drugs, among which cannabis is one of the most common. The aim of the present study was to evaluate, using the conditioned place preference, the effect of the cannabinoid agonist WIN 55,212-2 on the rewarding effects of MDMA in mice.MethodsIn the first experiment adolescent mice were initially conditioned with 1.25, 2.5 or 5 mg/kg of MDMA or 0.1 or 0.5 mg/kg of WIN and subsequently with both drugs. Reinstatement of the extinguished preference by priming doses was performed in the groups that showed CPP. In the second experiment, animals were conditioned with 2.5 or 5 mg/kg of MDMA and, after extinction, r…

MaleAgonistCannabinoid receptormedicine.drug_classMorpholinesN-Methyl-34-methylenedioxyamphetamineCognitive Neurosciencemedicine.medical_treatmentMice Inbred StrainsNaphthalenesPharmacologylcsh:RC346-429Extinction PsychologicalMiceBehavioral NeuroscienceSerotonin AgentsPiperidinesReceptor Cannabinoid CB1RewardRimonabantConditioning Psychologicalmental disordersmedicineAnimalsDrug Interactionslcsh:Neurology. Diseases of the nervous systemBiological PsychiatryBrain ChemistryBehavior AnimalDose-Response Relationship DrugbiologyResearchMDMAGeneral MedicineExtinction (psychology)Calcium Channel Blockersbiology.organism_classificationConditioned place preferenceBenzoxazinesNeuroprotective AgentsPyrazolesCannabinoidCannabisRimonabantPsychologypsychological phenomena and processesmedicine.drugBehavioral and Brain Functions
researchProduct

Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference

2011

Cannabis is one of the drugs most commonly consumed in combination with ecstasy (3,4-methylenedioxymethamphetamine, MDMA). Although numerous studies have attempted to further our understanding of the role of the cannabinoid system in drug abuse, few have focused on how it influences the rewarding effects of MDMA. The aim of the present study was to evaluate the role of the CB1 cannabinoid receptor in vulnerability to reinstatement of a MDMA-induced conditioned place preference (CPP). Mice were first conditioned with 5mg/kg of MDMA. Once the preference had been extinguished, a priming dose of MDMA, alone or plus the CB1 cannabinoid agonist WIN 55,212-2 (0.1 and 0.5mg/kg) or the CB1 cannabino…

MaleAgonistCannabinoid receptormedicine.drug_classMorpholinesN-Methyl-34-methylenedioxyamphetaminemedicine.medical_treatmentDrug-Seeking BehaviorClinical BiochemistryEcstasyNaphthalenesPharmacologyToxicologyBiochemistryMiceBehavioral NeuroscienceReceptor Cannabinoid CB1Conditioning Psychologicalmental disordersmedicineAnimalsBiological PsychiatryPharmacologyDose-Response Relationship DrugCannabinoidsbusiness.industrymusculoskeletal neural and ocular physiologyAntagonistMDMAEndocannabinoid systemConditioned place preferenceBenzoxazinesnervous systemlipids (amino acids peptides and proteins)Cannabinoidbusinesspsychological phenomena and processesmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (r)-(+)-[2,3-dihydro-5-methyl-3-(4-m…

2003

The aim of the present in vivo microdialysis study was to investigate whether prenatal exposure to the CB1 receptor agonist WIN55,212-2 mesylate (WIN; (R)-()-(2,3- dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo(1,2,3-de)- 1,4-benzoxazin-6-yl)-1-naphthalenylmethanone), at a dose of 0.5 mg/kg (s.c. from the fifth to the 20th day of gestation), that causes neither malformations nor overt signs of toxicity, influences cortical glutamate extracellular levels in adult (90- day old) rats. Dam weight gain, pregnancy length and litter size at birth were not significantly affected by prenatal treatment with WIN. Basal and K-evoked dialysate glutamate levels were lower in the cerebral cortex of adul…

MaleAgonistmedicine.medical_specialtyMicrodialysisTime FactorsCannabinoid receptormedicine.drug_classMicrodialysisMorpholinesGlutamic Acidmaternal marijuana consumptionNaphthalenesBiologyTimechemistry.chemical_compoundGlutamatergicPiperidinesPregnancyInternal medicinebasal and K -evoked glutamate levelsmedicineAnimalsDrug InteractionsWakefulnessNeurotransmitterReceptorSR141716A; basal and K+-evoked glutamate levels; maternal marijuana consumptionCerebral CortexAnalysis of VarianceDose-Response Relationship DrugCannabinoidsGeneral NeuroscienceGlutamate receptorBenzoxazinesRatsEndocrinologyAnimals NewbornchemistryPrenatal Exposure Delayed EffectsSR141716AToxicityPotassiumPyrazolesSR141716A; basal and K -evoked glutamate levels; maternal marijuana consumption.CalciumFemaleRimonabantExtracellular Space
researchProduct

Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.

2007

Abstract While most of the studies concerning the role of cannabinoids on gastric motility have focused the attention on the gastric emptying in in vivo animal models, there is little information about the cannabinoid peripheral influence in the stomach. In addition, the functional features of CB2 receptors in the gastrointestinal tract have been poorly characterized. The purpose of the present study was to investigate the effects of cannabinoid drugs on the excitatory cholinergic and inhibitory non-adrenergic non-cholinergic (NANC) neurotransmission in mouse isolated gastric preparations. Intraluminal pressure from isolated whole stomach was recorded and mechanical responses induced by ele…

MaleCB1 receptorCannabinoid receptorIndolesmedicine.medical_treatmentGastric motilityReceptors PresynapticSettore BIO/09 - FisiologiaSynaptic TransmissionReceptor Cannabinoid CB2MicePiperidinesReceptor Cannabinoid CB1Cannabinoid receptor type 2StomachCholinergic Fiberslipids (amino acids peptides and proteins)Rimonabantmedicine.drugAgonistmedicine.medical_specialtyCarbacholmedicine.drug_classPolyunsaturated AlkamidesMorpholinesNeuromuscular JunctionArachidonic AcidsBiologyIn Vitro TechniquesNaphthalenesInternal medicineCannabinoid Receptor ModulatorsmedicineAnimalsCannabinoidPharmacologyEnteric neurotransmissionGastric emptyingCannabinoidsExcitatory Postsynaptic PotentialsCB2 receptorElectric StimulationBenzoxazinesMice Inbred C57BLEndocrinologyInhibitory Postsynaptic PotentialsCholinergicPyrazolesCannabinoidGastrointestinal MotilityGastric motilityEndocannabinoidsPharmacological research
researchProduct

Protective activation of the endocannabinoid system during ischemia in dopamine neurons

2006

Endocannabinoids act as neuroprotective molecules promptly released in response to pathological stimuli. Hence, they may represent one component of protection and/or repair mechanisms mobilized by dopamine (DA) neurons under ischemia. Here, we show that the endocannabinoid 2-arachidonoyl-glycerol (2-AG) plays a key role in protecting DA neurons from ischemia-induced altered spontaneous activity both in vitro and in vivo. Accordingly, neuroprotection can be elicited through moderate cannabinoid receptor type-1 (CB1) activation. Conversely, blockade of endocannabinoid actions through CB1 receptor antagonism worsens the outcome of transient ischemia on DA neuronal activity. These findings indi…

MaleCannabinoid receptorDopaminePharmacologyBrain IschemiaMidbrainRats Sprague-DawleyMicePiperidinesReceptor Cannabinoid CB1IschemiaPremovement neuronal activityReceptorMice KnockoutNeuronsmusculoskeletal neural and ocular physiologyEndocannabinoid systemCB1NeuroprotectionElectrophysiologyNeurologylipids (amino acids peptides and proteins)Rimonabantpsychological phenomena and processesmedicine.drugSignal TransductionMorpholinesIschemiaArachidonic AcidsBiologyIn Vitro TechniquesNaphthalenesNeuroprotectionAmidohydrolasesGlycerideslcsh:RC321-571DopamineCannabinoid Receptor ModulatorsmedicineAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryEndocannabinoidVentral Tegmental Areamedicine.diseaseBlockadeBenzoxazinesRatsnervous systemPyrazolesNeuroscienceEndocannabinoidsNeurobiology of Disease
researchProduct